VTAK Announces Preliminary Second Quarter Record Revenue in Excess of $1 million
Rhea-AI Summary
Catheter Precision (NYSE American: VTAK) reported preliminary unaudited record revenue of $1,037,000 for the quarter ended June 30, 2026, combining its MedTech and Flyte Vision Jet segments. The Flyte Vision Jet segment generated $767,000, up 61% sequentially over Q1 2026, while the MedTech segment grew 27% over Q2 2025.
According to the company, preliminary revenue for the first two weeks of July 2026 exceeded $400,000. Catheter Precision is also working with an outside investment bank to evaluate alternative scenarios for its MedTech segment and aims to finalize related plans over the next several months.
Positive
- Q2 2026 preliminary revenue $1.037 million, record quarter
- Flyte Vision Jet Q2 revenue $767,000, up 61% sequentially
- MedTech segment revenue up 27% versus Q2 2025
- First two weeks July 2026 revenue over $400,000
Negative
- None.
Market reaction after 2Q26 preliminary revenue update: VTAK +3.57% in the Jul 15 session
In the Jul 15 session, VTAK gained 3.57%, reflecting a moderate positive market reaction. Argus tracked a peak move of +18.4% during that session. Argus tracked a trough of -21.8% from its starting point during tracking. Our momentum scanner triggered 70 alerts that day, indicating high trading interest and price volatility. Trading volume was elevated at 2.5x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 07 | Safety partnership | Positive | +92.2% | Flyte-LifeVac deal to equip every Vision Jet with airway devices. |
| Jul 06 | Patent issuance | Positive | -3.0% | Two key patents for VIVO mapping and Cardionomix platform. |
| Jul 02 | Booking platform launch | Positive | -8.7% | Flyte’s direct-to-consumer platform driving about 170% sequential revenue growth. |
| Jun 22 | Sports marketing deal | Positive | +5.8% | GSE Worldwide and Emiliano Grillo partnership debuting at the U.S. Open. |
| Jun 22 | Strategic investment | Neutral | +3.5% | Volato PIPE financing with Catheter Precision as a strategic investor. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent VTAK news has produced mixed reactions, with some strong rallies but also notable selloffs following seemingly positive operational updates.
Key Terms
cardiac electrophysiology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Flyte Vision Jet Segment up
MedTech segment up
FORT MILL, S.C., July 15, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK: NYSE/American), today announced preliminary unaudited record revenues of
David Jenkins, CEO of Catheter Precision, Inc., commented, “We are extremely pleased as to the revenue growth of the company, including the growth in both segmented areas. We are especially pleased with the acquisition of Fly Flyte, Inc., and its promise for the future. As we bring on additional Vision Jets into our fleet, and recruit, train, and certify new pilots, we believe our company should be poised to transition from a million-dollar quarter to a million-dollar month before the end of the year. In fact, our preliminary revenue for just the first two weeks of July (2026) is over
Mr. Jenkins continued, “We continue to work with an outside investment bank to enhance shareholder value through alternative scenarios envisioned for our MedTech segment. Cardiac electrophysiology is one of the largest growth areas in medical devices today, and we believe our technology offers substantial value to physicians and associated patient care. Our goal is to solidify our MedTech plans over the next several months.”
About VTAK
The MedTech segment, Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
The aviation segment, Flyte, is a private aviation company operating a growing fleet of Cirrus Vision Jets and providing efficient short-haul travel solutions throughout the United States.
Flight operations are conducted through Flyte's wholly owned subsidiary, Ponderosa Air, LLC, an FAA-certified Part 135 air carrier. With certified aircraft, active revenue-generating operations, and scalable fleet expansion underway, Flyte is building disciplined aviation infrastructure designed to deliver a faster, safer, and more efficient alternative to traditional private charter travel.
Preliminary Second Quarter 2026 Results
This press release sets forth certain preliminary estimates of financial and operating results that we expect to report for the second quarter ended June 30, 2026. We are currently in the process of finalizing our financial results for the June 30, 2026 second quarter, and the preliminary estimated financial information presented above reflects various assumptions and estimates based upon preliminary information available to us as of the date of this press release. This information should not be viewed as a substitute for full unaudited financial statements prepared in accordance with accounting principles generally accepted in the United States for the second quarter ended June 30, 2026. Our independent registered public accounting firm has not reviewed this preliminary estimated financial information. As a result, it remains in all cases subject to change pending finalization. Items or events may be identified or occur after issuance of these preliminary results due to the completion of operational and financial closing procedures. In addition, final adjustments and other developments may arise that would require us to make material adjustments to this preliminary financial information.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding our belief our company should be poised to transition from a million-dollar quarter to a million-dollar month before the end of the year. These and other risks are detailed in the Company’s filings with the Securities and Exchange Commission, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
